Cobenfy: A New Frontier In Schizophrenia Treatment Faces Early Challenges
In September 2024, the U.S. Food and Drug Administration (FDA) approved Cobenfy (xanomeline and trospium…
News
Why Is Auvelity The Future Of Depression Care?
Major depressive disorder (MDD) has been ranked as the third cause of the burden of…
Flyrcado™ : A Breakthrough In Cardiac PET Imaging For Coronary Artery Disease
In a landmark advancement for nuclear cardiology, GE HealthCare has launched Flyrcado™ (flurpiridaz F 18), the first FDA-approved unit-dose…
FDA Approves Itovebi: A New Targeted Therapy For Advanced Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved Itovebi™ (inavolisib), developed by Genentech, a…
Orlynvah Offers Hope Amid Rising Antibiotic Resistance In UTI Treatments
In October 2024, the U.S. Food and Drug Administration (FDA) approved Orlynvah™ (sulopenem etzadroxil and…
Ziihera: A New Hope For HER2-Positive Biliary Tract Cancer Patients
In November 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Ziihera®…
Attruby: A Game-Changer In ATTR-CM Treatment With Record-Breaking Sales And Clinical Success
FDA Approval Attruby Market Impact Attruby™ (acoramidis), developed by BridgeBio Pharma, received FDA approval in…
Bizengri A Breakthrough Targeted Therapy For NRG1 Fusion-Positive Cancers
Bizengri represents a paradigm shift in treating NRG1+ cancers, offering hope for patients with historically poor prognoses.…
FDA Approves Kisunla: A New Hope In Early Alzheimer’s Treatment
April 18, 2025 — Phoenix, AZ — In a significant advancement for Alzheimer’s disease treatment,…
Checkpoint Therapeutics Achieves Milestone With Unloxcyt™ Approval For Advanced Skin Cancer
In a significant advancement for oncology therapeutics, the U.S. Food and Drug Administration (FDA) approved…
Copyright@ 2016-2024 Hong Kong Deng Yue Med Al Rights